U.S. Hospitality Stock News

NasdaqGS:NXPI
NasdaqGS:NXPISemiconductor

NXP Semiconductors (NXPI) Margin Decline Challenges Bullish Earnings Growth Narratives

NXP Semiconductors (NXPI) just wrapped up FY 2025 with Q4 revenue of US$3.3b and basic EPS of US$1.80, anchored by net income of US$455m, setting the stage for how investors read the year as a whole. The company has seen quarterly revenue move from US$3.1b in Q4 2024 to US$3.3b in Q4 2025, alongside quarterly EPS shifting from US$1.95 to US$1.80, which feeds into trailing twelve month EPS of US$8.00 on revenue of US$12.3b. With trailing net income of US$2.0b and a reported net margin that has...
OTCPK:SGMO
OTCPK:SGMOBiotechs

What Sangamo Therapeutics (SGMO)'s Fabry Gene Therapy Progress And Equity Raise Means For Shareholders

Sangamo Therapeutics recently reported detailed Phase 1/2 STAAR study results for its Fabry disease gene therapy, isaralgagene civaparvovec, and confirmed a rolling Biologics License Application submission to the FDA under the Accelerated Approval pathway, supported by kidney function as an intermediate clinical endpoint. The company paired these clinically promising data and regulatory progress with a roughly US$24.82 million follow-on equity raise and a finance leadership change,...
NYSE:HMN
NYSE:HMNInsurance

Is Horace Mann Educators (HMN) Price Justified After 5-Year 36.7% Share Return?

If you are wondering whether Horace Mann Educators at around US$44.92 still offers value, an important question is how its current price compares with what the business may be worth. The stock has returned 4.7% over the last 7 days, while the 1 year return sits at 21.7% and the 3 year return at 38.6%. A 0.6% decline year to date may suggest that expectations and risk perceptions are changing. Recent coverage has focused on Horace Mann Educators as an insurer serving the education community,...
NasdaqGM:SGMT
NasdaqGM:SGMTBiotechs

Why Sagimet Biosciences (SGMT) Is Up 7.7% After Denifanstat’s Phase 3 Acne Success And What's Next

Sagimet Biosciences recently reported that Ascletis Pharma’s Phase 3 trial of ASC40 (Denifanstat) for acne met all primary and secondary endpoints and was well-tolerated, with no serious adverse events observed. The results highlight fatty acid synthase (FASN) inhibition as a potentially new way to treat acne, with findings slated for presentation at upcoming medical congresses and in scientific publications. Next, we’ll examine how Denifanstat’s Phase 3 success in acne may influence Sagimet...
NasdaqGS:UVSP
NasdaqGS:UVSPBanks

Exploring 3 Undervalued Small Caps With Insider Buying Activity

As February begins, U.S. stock markets have shown a strong start with major indices like the Dow Jones and S&P 500 climbing significantly, reflecting positive sentiment despite broader economic uncertainties such as delayed job reports due to a government shutdown. In this environment of fluctuating market dynamics, small-cap stocks often present unique opportunities for investors looking for potential growth, particularly when insider buying activity suggests confidence from those closest to...